OPKO Health announces U.S. launch of RAYALDEE
OPKO Health announced that it will commence shipments of RAYALDEE extended-release capsules to distributors in the United States on Tuesday, November 29. The product will be available nationwide at retail pharmacies as early as Wednesday, November 30, the company said. Phillip Frost, M.D., CEO and Chairman of OPKO, said, "RAYALDEE is the first product developed by OPKO to be commercialized by our own marketing and sales teams, and represents an important contribution to the care of patients with chronic kidney disease. Based on the highly positive reception of RAYALDEE by nephrologists attending the recent ASN meeting, we believe that RAYALDEE will become a mainstay in the armamentarium of treatment options available for kidney disease patients."